AVIGI Therapeutics is developing first-in-class covalent inhibitors targeting heparanase, a key enzyme in extracellular matrix homeostasis, addressing some of the most difficult-to-treat conditions in human health, beginning with cancer and extending to inflammatory diseases and renal disorders.
Allow the use of cookies from this website on this browser?
We use cookies to provide improved experience on this website. You can learn more about our cookies and how we use them in our Privacy & Cookie Policy.